Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -4034.35% is 52% below its 5-year average of -2655.70%, around the middle of its 5-year range (-9964.71%–4.90%).
22.68% above its 12-month average of -5217.84%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -4574.78%.
EBITDA MARGIN
-4034.35%
EBITDA MARGIN AVG TTM
-5217.84%
EBITDA MARGIN AVG 3Y
-5217.84%
EBITDA MARGIN AVG 5Y
-2655.70%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+22.68%
CURRENT VS 3Y AVG
+22.68%
CURRENT VS 5Y AVG
-51.91%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Milestone Pharmaceuticals Inc.
Market Cap
$95.95M
EBITDA Margin
-4034.35%
TTM Avg
-5217.84%
3Y Avg
-5217.84%
5Y Avg
-2655.70%
Market Cap
$94.76M
EBITDA Margin
-1299.47%
TTM Avg
-2594.80%
3Y Avg
-2594.80%
5Y Avg
-1753.28%
Market Cap
$98.16M
EBITDA Margin
-5221.43%
TTM Avg
-5221.43%
3Y Avg
-3887.65%
5Y Avg
-3386.47%
Market Cap
$92.88M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$91.24M
EBITDA Margin
-35.83%
TTM Avg
-39.56%
3Y Avg
-111.97%
5Y Avg
-250.85%
Market Cap
$90.38M
EBITDA Margin
15.84%
TTM Avg
9.89%
3Y Avg
0.86%
5Y Avg
4.00%
Market Cap
$89.15M
EBITDA Margin
-19.79%
TTM Avg
-29.84%
3Y Avg
-150.95%
5Y Avg
-150.95%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Milestone Pharmaceuticals Inc. (MIST) | $95.95M | -4034.35% | -5217.84% | -5217.84% | -2655.70% |
| Korro Bio, Inc. (KRRO)vs › | $94.76M | -1299.47% | -2594.80% | -2594.80% | -1753.28% |
| Anixa Biosciences, Inc. (ANIX)vs › | $98.16M | -5221.43% | -5221.43% | -3887.65% | -3386.47% |
| Neumora Therapeutics, Inc. Common Stock (NMRA)vs › | $92.88M | N/A | N/A | N/A | N/A |
| The Joint Corp. (JYNT)vs › | $101.21M | 1.47% | 3.45% | 8.31% | 9.97% |
| electroCore, Inc. (ECOR)vs › | $91.24M | -35.83% | -39.56% | -111.97% | -250.85% |
| ImmuCell Corporation (ICCC)vs › | $90.38M | 15.84% | 9.89% | 0.86% | 4.00% |
| Biomea Fusion, Inc. (BMEA)vs › | $90.01M | N/A | N/A | N/A | N/A |
| Equillium, Inc. (EQ)vs › | $89.15M | -19.79% | -29.84% | -150.95% | -150.95% |
| Definitive Healthcare Corp. (DH)vs › | $104.99M | 6.31% | -127.53% | -89.97% | -50.55% |
Gross Margin
94.6%
EBITDA Margin
-4034.3%
Operating Margin
-4041.7%
Net Margin
-3585.6%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -4574.78% |
| 2026-03-31 | -9964.71% |
| 2025-12-31 | -1114.04% |
| 2023-03-31 | -1548.40% |
| 2022-12-31 | -392.69% |
| 2022-09-30 | -1000.20% |
| 2021-06-30 | 4.90% |
